Mergers

Poison Pill: How Shareholder Rights Plans Work

A poison pill gives every holder discounted stock if one investor crosses a set ownership line, usually 10% to 20%. Seven 2026 plans, led by Wendy's response to Trian, show the triggers, expiries, NOL variant and how pills end.

Poison Pill: How Shareholder Rights Plans Work

A poison pill, formally a shareholder rights plan, is a board-adopted defense that hands every holder a right to buy discounted stock the moment any one investor crosses a set ownership line, usually 10% to 20%, while the investor who crossed it gets nothing. The dilution makes creeping control too expensive, so a would-be buyer has to negotiate with the board or replace it. Pills do not need a shareholder vote to adopt, they usually last about a year, and 2026 has produced a steady run of them, from Wendy's to Coursera.

How a rights plan works

The board declares a dividend of one right per common share. Until a trigger event, the rights are invisible: they trade attached to the stock and cannot be exercised. The trigger is someone becoming an "Acquiring Person."

The Wendy's 8-K filed November 5, 2026 describes the standard design in plain terms: the plan "works by imposing significant dilution upon any person or group that acquires fifteen percent (15%) or more of the Common Shares (including in economic exposure through certain derivatives contracts...)" without board approval. The pieces:

  • Trigger threshold. 15% at Wendy's. Holders already above the line on announcement day are grandfathered at their current stake, but buying more trips the plan.
  • Distribution Date. At Wendy's, the close of business on the 10th day after public announcement that someone became an Acquiring Person. That is when rights separate from the shares.
  • Flip-in. Every holder except the Acquiring Person may pay the $37.00 purchase price for common stock "with a then-current market value of twice the Purchase Price." The Acquiring Person's rights become "null and void."
  • Exchange. Before the Acquiring Person reaches 50%, the board may instead swap one common share for each right, with no cash changing hands.
  • Flip-over. If the company is later merged or sells 50% or more of its assets, rights convert into the acquirer's stock at the same two-for-one value.
  • Redemption and expiry. Boards can redeem rights for a fraction of a cent before the trigger ($0.001 per right at Xponential and Dine Brands). Wendy's rights expire at the close of business on November 3, 2027.

2026 poison pills: trigger, expiry and reason

An EDGAR full-text search for "rights agreement" in 2026 8-Ks with Item 3.03 turns up dozens of adoptions, extensions and terminations. Seven recent US-listed examples, each from the company's own 8-K or press release:

CompanyAdoptedTriggerExpiresStated reason
Wendy's ($WEN)Nov 4, 202615%Nov 3, 2027Trian-led group's $7.35 proposal; group rejected a standstill
Coursera ($COUR)Nov 7, 202615%Nov 7, 2027A holder had built a stake of about 14.7%
Liberty Media ($FWONK)Nov 4, 202610% (15% passive)Nov 3, 2027Guard against open-market accumulation amid volatility
Dine Brands ($DIN)Oct 28, 202610% (20% passive)Oct 27, 2027Ensure any buyer pays a control premium
Xponential Fitness ($XPOF)Oct 12, 202619.9%Oct 11, 2027"Recent significant accumulation"; strategic review under way
Sabre ($SABR)Mar 1, 202615% (20% for 13G filers)Feb 28, 2027Constellation Software's 9.7% economic position
CNO Financial ($CNO)Nov 13, 2026 (sixth restatement)4.99%Nov 13, 2029*Protect tax net operating loss carryforwards

*CNO's rights expire November 13, 2027 if shareholders have not approved the restated plan by then. Sources: each company's 8-K on SEC EDGAR; Sabre's and Xponential's press releases (Exhibit 99.1).

Two patterns stand out. 15% is the most common trigger in the table, and both 10% plans carve out a higher line for passive investors. Six of the seven run about one year; Wendy's, Sabre, Xponential and Coursera each call their plan "limited-duration." Sabre's release is the most detailed on motive: Constellation built "4.7% beneficial ownership of common stock and a further 5% via derivative instruments," which is why modern plans count swaps toward the trigger.

NOL pills and the 4.99% line

A tax-asset pill protects net operating losses, not control. Under Section 382 of the Internal Revenue Code, an "ownership change" occurs when stock owned by "1 or more 5-percent shareholders has increased by more than 50 percentage points" over a testing period that is generally three years. Such a change limits how much prior loss a company can use. So NOL pills trigger just under 5%. CNO's plan targets any new holder of "4.99% or more" and lets existing 4.99% holders add no more than one additional percentage point. This is general information about what the statute says, not tax advice.

Worked example: the flip-in at Wendy's

The math below uses Wendy's real plan terms and real share data, with a hypothetical buyer. Wendy's reported 191,242,899 shares outstanding on its latest 10-Q cover, and the stock closed at $8.91 on November 18, 2026. Assume, hypothetically, that an unapproved investor reaches exactly 15% and the board uses the exchange feature, one new share per right held by everyone else.

StepCalculationResult
Acquiring Person's shares191,242,899 × 15%28,686,435
Rights still valid (everyone else)191,242,899 − 28,686,435162,556,464
Shares after the 1-for-1 exchange191,242,899 + 162,556,464353,799,363
Acquiring Person's new stake28,686,435 ÷ 353,799,3638.11%
Stake value before28,686,435 × $8.91$255.6 million
Value per share after, same total equity(191,242,899 × $8.91) ÷ 353,799,363$4.82
Stake value after28,686,435 × $4.82$138.2 million (−45.9%)

Other holders are made whole because each gets an extra share. The buyer alone loses about $117.4 million on paper. If the rights were exercised for cash instead, each $37 payment would buy $74 of stock, or 8.31 shares at $8.91, and the dilution would be far larger. The exchange is simply the easier case to model.

How pills shape takeover and activist fights

A pill does not stop a bid. It stops a bidder from buying control in the market. That leaves three paths: negotiate with the board, make an offer conditioned on the board redeeming the rights, or win a proxy fight and install directors who will redeem them. Wendy's said its plan "does not contain any dead-hand, slow-hand, no-hand or similar feature," so a future board could redeem it.

The board's leverage is time. Trian's group proposed $7.35 a share on October 28, 2026, which values all 191.2 million shares at about $1.41 billion. Wendy's independent committee rejected it on November 5 as substantially undervaluing the company, and TTFY covered the standoff in Wendy's poison pill sets up activist takeover battle. Boards that sign a friendly deal still face the vote, as the failed H&R REIT arrangement showed in Canada, where that deal ran as a plan of arrangement.

What happens to the stock

There is no fixed reaction. The price tends to follow the news that arrives with the pill, not the pill itself. Closes from Yahoo Finance (more deal coverage is on the Trading Tips For You homepage):

  • Sabre: $1.18 on February 27, 2026, then $1.61 on March 2, the first session after the Sunday announcement that named Constellation (+36.4%).
  • Wendy's: $7.65 on November 4, then $7.94 on November 5, the day of the rejection, the pill and Q3 results (+3.8%). It closed at $8.91 on November 18, 21.2% above the $7.35 proposal (8.91 ÷ 7.35 − 1).
  • Coursera: $3.74 on November 6, then $3.75 on November 9 (+0.3%).
  • Xponential: $4.95 on October 9, then $4.81 on October 12 (−2.8%).

How a pill ends

  • It expires. Most 2026 plans lapse after about a year unless renewed.
  • It is redeemed or accelerated. Sturm Ruger ($RGR) moved its rights' final expiration from October 13, 2026 to September 16, 2026. Lee Enterprises ($LEE) ended its plan on February 4, 2026, alongside a share sale after which an anchor investor held about 52%.
  • A deal closes. Dine Brands' rights expire at the closing of a board-approved merger.
  • Shareholders vote it down. Some plans need ratification: CNO's lapses in 2027 without approval, and International Seaways ($INSW) said it expected to seek ratification of its extended plan at its 2026 annual meeting.

Common mistakes

  1. Reading a pill as a "no." Wendy's says its plan is not intended to stop offers that are fair. It forces talks; it does not end them.
  2. Treating the rights as a separate asset. Before the Distribution Date they trade with the stock and are worth nothing on their own.
  3. Ignoring derivatives. Wendy's, Xponential and Sabre count economic exposure from swaps toward the trigger.
  4. Mixing up 4.99% and 5%. An NOL pill trips just below the 5% level that also requires a Schedule 13D filing.
  5. Taking the expiry date as fixed. Ruger shortened its plan, while CNO and International Seaways extended theirs.

Bull/Bear Verdict

Bull Case: A pill can push a bidder to negotiate with the board rather than buy control cheaply. When the target stays in play, holders can benefit: Wendy's closed 21.2% above Trian's $7.35 proposal on November 18, 2026.

Bear Case: A pill can also keep a sale off the table. Boards adopt it without a vote, can renew it, and in the four cases above, first-day moves ranged from −2.8% to +36.4%, so the pill itself is no reliable signal.

FAQ

Do shareholders need to do anything when a pill is adopted?

No. Rights are issued automatically to holders on the record date (November 16, 2026 at Wendy's) and trade with the shares unless the plan is triggered.

What is the usual poison pill trigger?

Among the 2026 plans above, 15% is most common. Liberty Media and Dine Brands use 10% for active investors, Xponential uses 19.9%, and NOL pills such as CNO's use 4.99%.

Can an activist still win with a pill in place?

Yes, through a proxy fight or a negotiated deal. A pill limits buying more stock, not voting the stock already owned.

How long does a poison pill last?

Six of the seven 2026 plans above run about one year. NOL plans can run longer: CNO's runs to 2029 if shareholders approve it.

Share X LinkedIn Email
Disclaimer: The information provided is for informational purposes only and is not intended as financial, legal, or tax advice. Trading around earnings involves significant risk and increased volatility. Past performance is not indicative of future results. No strategy can guarantee profits or protect against loss. Consult a professional advisor before acting on any information provided.

More in Mergers · Full archive